Annexon Biosciences (ANNX)

ANNX · BiotechSign Pipeline

Pipeline Overview

Therapeutic Focus: Neurosciencesrc

Signal Snapshot

Clinical Trials (ClinicalTrials.gov aggregate)

Catalyst Records

Publications on Record

ClinicalTrials.gov aggregate as of 2026-09-29. Source

Recent Publications

Incidence of dementia and mild cognitive impairment in two Indigenous Bolivian cohorts. — Alzheimers Dement (2026) PMID 42742085
Risk of transmission of amyloid β pathology via transfused blood products. — Lancet (2026) PMID 42624157

5 total publications tracked — view all on BiotechSign

Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for Annexon Biosciences.

Full ANNX Data Sign Up Free

Primary Sources

Company identity
Therapeutic indication
Clinical trial aggregate
Publication 42742085
Publication 42624157
Publication 42583778
Publication 42558353
Publication 42545715

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.